RS63674B1 - Lečenje simptoma kognitivnih i poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 - Google Patents
Lečenje simptoma kognitivnih i poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5Info
- Publication number
- RS63674B1 RS63674B1 RS20220892A RSP20220892A RS63674B1 RS 63674 B1 RS63674 B1 RS 63674B1 RS 20220892 A RS20220892 A RS 20220892A RS P20220892 A RSP20220892 A RS P20220892A RS 63674 B1 RS63674 B1 RS 63674B1
- Authority
- RS
- Serbia
- Prior art keywords
- compounds
- iii
- test
- compound
- animals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310409P | 2016-03-18 | 2016-03-18 | |
| EP17767701.0A EP3439665B1 (en) | 2016-03-18 | 2017-03-20 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
| PCT/US2017/023206 WO2017161370A1 (en) | 2016-03-18 | 2017-03-20 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63674B1 true RS63674B1 (sr) | 2022-11-30 |
Family
ID=59851645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220892A RS63674B1 (sr) | 2016-03-18 | 2017-03-20 | Lečenje simptoma kognitivnih i poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10906909B2 (enExample) |
| EP (2) | EP4129297A1 (enExample) |
| JP (2) | JP7023876B2 (enExample) |
| AU (2) | AU2017235665B2 (enExample) |
| CA (1) | CA3016491A1 (enExample) |
| CY (1) | CY1125576T1 (enExample) |
| DK (1) | DK3439665T3 (enExample) |
| ES (1) | ES2926918T3 (enExample) |
| HR (1) | HRP20221098T1 (enExample) |
| HU (1) | HUE059774T2 (enExample) |
| LT (1) | LT3439665T (enExample) |
| PL (1) | PL3439665T3 (enExample) |
| PT (1) | PT3439665T (enExample) |
| RS (1) | RS63674B1 (enExample) |
| SI (1) | SI3439665T1 (enExample) |
| SM (1) | SMT202200372T1 (enExample) |
| WO (1) | WO2017161370A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017313753B2 (en) | 2016-08-16 | 2022-01-27 | The Trustees Of Columbia University In The City Of New York | GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma |
| US12636291B2 (en) * | 2019-02-13 | 2026-05-26 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors |
| WO2020191047A1 (en) * | 2019-03-18 | 2020-09-24 | Neurocycle Therapeutics, Inc. | Use of gabaa receptor modulators for treatment of pain |
| US12649738B2 (en) | 2020-03-26 | 2026-06-09 | Richter Gedeon Nyrt. | 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| JP2024533306A (ja) * | 2021-09-08 | 2024-09-12 | ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド | 認知および気分症状の処置のためのイミダゾベンゾジアゼピン |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| WO2023059443A1 (en) * | 2021-10-07 | 2023-04-13 | Pantherics Incorporated | Methods and compounds for treating inflammation |
| US20260125388A1 (en) * | 2022-10-04 | 2026-05-07 | Uwm Research Foundation, Inc. | Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation |
| IT202400001089A1 (it) * | 2024-01-22 | 2025-07-22 | Fondazione St Italiano Tecnologia | Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA755418B (en) | 1974-09-11 | 1977-06-29 | Hoffmann La Roche | Diazepine derivatives |
| US4226768A (en) | 1979-05-29 | 1980-10-07 | Hoffmann-La Roche Inc. | Process for the preparation of imidazobenzodiazepines |
| US20030176456A1 (en) | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| USRE47475E1 (en) | 2002-03-28 | 2019-07-02 | Wisys Technology Foundation, Inc. | Selective agents for pain suppression |
| WO2003082832A2 (en) | 2002-03-28 | 2003-10-09 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| US8835424B2 (en) | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
| AU2005260650A1 (en) | 2004-06-30 | 2006-01-12 | Wisys Technology Foundation, Inc. | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| US7595395B2 (en) * | 2005-05-16 | 2009-09-29 | Wisys Technology Foundation | Gabaergic agents to treat memory deficits |
| US20100130479A1 (en) | 2005-05-16 | 2010-05-27 | Cook James M | Gabaergic Agents to Treat Memory Deficits |
| US7858649B2 (en) | 2005-10-14 | 2010-12-28 | Neurosearch A/S | Imidazole derivatives and their use for modulating the GABAA receptor complex |
| DE102006023554A1 (de) | 2006-05-19 | 2007-11-22 | Zf Friedrichshafen Ag | Ermittlung der Drehzahl einer Getriebewelle |
| US8119629B2 (en) | 2007-10-03 | 2012-02-21 | Bristol-Meyers Squibb Company | Carboxamide GABAA α2 modulators |
| US8923318B2 (en) | 2008-10-02 | 2014-12-30 | Telefonaktiebolaget L M Ericsson (Publ) | Wireless communication system and method for assigning a channel in said wireless communication system |
| US20100261711A1 (en) | 2009-03-20 | 2010-10-14 | Wisys Technology Foundation | Selective anticonvulsant agents and their uses |
| US9006233B2 (en) | 2011-04-28 | 2015-04-14 | Uwm Research Foundation, Inc. | Gabaergic receptor subtype selective ligands and their uses |
| CA2885148A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
| WO2016154031A1 (en) | 2015-03-20 | 2016-09-29 | Uwm Research Foundation, Inc. | Gabaergic ligands and their uses |
-
2017
- 2017-03-20 EP EP22181243.1A patent/EP4129297A1/en active Pending
- 2017-03-20 DK DK17767701.0T patent/DK3439665T3/da active
- 2017-03-20 SM SM20220372T patent/SMT202200372T1/it unknown
- 2017-03-20 WO PCT/US2017/023206 patent/WO2017161370A1/en not_active Ceased
- 2017-03-20 ES ES17767701T patent/ES2926918T3/es active Active
- 2017-03-20 HU HUE17767701A patent/HUE059774T2/hu unknown
- 2017-03-20 PL PL17767701.0T patent/PL3439665T3/pl unknown
- 2017-03-20 LT LTEPPCT/US2017/023206T patent/LT3439665T/lt unknown
- 2017-03-20 EP EP17767701.0A patent/EP3439665B1/en active Active
- 2017-03-20 RS RS20220892A patent/RS63674B1/sr unknown
- 2017-03-20 PT PT177677010T patent/PT3439665T/pt unknown
- 2017-03-20 AU AU2017235665A patent/AU2017235665B2/en active Active
- 2017-03-20 JP JP2018568186A patent/JP7023876B2/ja active Active
- 2017-03-20 SI SI201731230T patent/SI3439665T1/sl unknown
- 2017-03-20 CA CA3016491A patent/CA3016491A1/en active Pending
- 2017-03-20 US US16/086,053 patent/US10906909B2/en active Active
- 2017-03-20 HR HRP20221098TT patent/HRP20221098T1/hr unknown
-
2020
- 2020-12-15 US US17/122,745 patent/US11753412B2/en active Active
-
2022
- 2022-02-08 JP JP2022017827A patent/JP7515526B2/ja active Active
- 2022-09-27 CY CY20221100636T patent/CY1125576T1/el unknown
- 2022-11-23 AU AU2022275446A patent/AU2022275446B2/en active Active
-
2023
- 2023-08-02 US US18/363,933 patent/US12180216B2/en active Active
-
2024
- 2024-11-12 US US18/944,947 patent/US20250179080A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017235665A1 (en) | 2018-09-27 |
| HUE059774T2 (hu) | 2023-01-28 |
| US20250179080A1 (en) | 2025-06-05 |
| EP3439665A4 (en) | 2019-11-27 |
| EP3439665A1 (en) | 2019-02-13 |
| CA3016491A1 (en) | 2017-09-21 |
| JP2019509340A (ja) | 2019-04-04 |
| DK3439665T3 (da) | 2022-09-26 |
| EP4129297A1 (en) | 2023-02-08 |
| JP7023876B2 (ja) | 2022-02-22 |
| PL3439665T3 (pl) | 2023-01-16 |
| US11753412B2 (en) | 2023-09-12 |
| ES2926918T3 (es) | 2022-10-31 |
| JP2022065035A (ja) | 2022-04-26 |
| US20240083905A1 (en) | 2024-03-14 |
| WO2017161370A1 (en) | 2017-09-21 |
| AU2022275446B2 (en) | 2025-01-02 |
| SI3439665T1 (sl) | 2023-05-31 |
| EP3439665B1 (en) | 2022-06-29 |
| SMT202200372T1 (it) | 2022-11-18 |
| US20210309662A1 (en) | 2021-10-07 |
| AU2017235665B2 (en) | 2022-12-08 |
| CY1125576T1 (el) | 2026-02-25 |
| LT3439665T (lt) | 2022-10-10 |
| WO2017161370A8 (en) | 2018-09-27 |
| US12180216B2 (en) | 2024-12-31 |
| AU2022275446A1 (en) | 2023-01-05 |
| US20200181146A1 (en) | 2020-06-11 |
| JP7515526B2 (ja) | 2024-07-12 |
| PT3439665T (pt) | 2022-09-27 |
| HRP20221098T1 (hr) | 2022-11-25 |
| US10906909B2 (en) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7515526B2 (ja) | α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置 | |
| CN102480956B (zh) | 吡啶并[4,3-b]吲哚类和使用方法 | |
| AU2015222805B2 (en) | Treatment of conditions associated with hyperinsulinaemia | |
| AU2017393082B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| US9006233B2 (en) | Gabaergic receptor subtype selective ligands and their uses | |
| CN102711466A (zh) | 桥连杂环化合物及其使用方法 | |
| KR20200096570A (ko) | 알츠하이머병과 같은 타우 응집체와 연관된 장애의 치료, 완화 또는 예방을 위한 1,3,4,5-테트라히드로-2h-피리도[4,3-b]인돌 유도체 | |
| US20200085795A1 (en) | Sphingosine 1 phosphate receptor agonists for neuroprotection | |
| US10259815B2 (en) | Gabaergic ligands and their uses | |
| BR112019011924A2 (pt) | derivados de bis-heteroarila bicíclicos como moduladores de agregação de proteína | |
| Epplin et al. | Discovery of dihydropyrrolo [1, 2-a] pyrazin-3 (4H)-one-based second-generation GluN2C-and GluN2D-selective positive allosteric modulators (PAMs) of the N-methyl-d-aspartate (NMDA) receptor | |
| US8829002B2 (en) | Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for production and use thereof | |
| US20240374612A1 (en) | Imidazobenzodiazepines for treatment of cognitive and mood symptoms | |
| US11472806B2 (en) | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | |
| JP2021522290A (ja) | １−イミダゾチアジアゾロ−２ｈ−ピロール−５−オン誘導体 | |
| JP7738924B2 (ja) | 新規ｖｄａｃ１阻害剤 |